Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.

Liu, Yifei; Skup, Martha; Yang, Min; Qi, Cynthia Z; Wu, Eric Q

Liu, Yifei; Skup, Martha; Yang, Min; Qi, Cynthia Z; Wu, Eric Q.

Afiliação

Liu Y; University of Missouri-Kansas City School of Pharmacy, 1228 Health Sciences Building, 2464 Charlotte Street, Kansas City, MO, 64108, USA. liuyif@umkc.edu.
Skup M; AbbVie, Chicago, IL, USA.
Yang M; Analysis Group, Inc., Boston, MA, USA.
Qi CZ; Analysis Group, Inc., Boston, MA, USA.
Wu EQ; Analysis Group, Inc., Boston, MA, USA.

Adv Ther ; 39(8): 3711-3734, 2022 08.

Article em En | MEDLINE | ID: mdl-35737227

Assuntos

Medicamentos Biossimilares; Reumatologia; Medicamentos Biossimilares/uso terapêutico; Humanos; Fatores Imunológicos; Infliximab; Inibidores do Fator de Necrose Tumoral/efeitos adversos; Fator de Necrose Tumoral alfa

Palavras-chave

Biosimilar; Discontinuation; Non-medical switch; Switchback; TNF inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reumatologia / Medicamentos Biossimilares Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google